Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,037 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,948 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06002828 | Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors | active not recruiting | — | 2,000 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06049134 | Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy | active not recruiting | Phase 4 | 30 | M.D. Anderson Cancer CenterOTHER | 1 |
| Sep 15, 2026 |
| clinicaltrials |
| NCT06215118 | A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) | active not recruiting | Phase 1 | 100 | PfizerINDUSTRY | 3 | Sep 15, 2026 | clinicaltrials |
| NCT06303167 | Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E) | active not recruiting | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06308822 | Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06647732 | Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT) | active not recruiting | Phase 2 | 42 | Sun Yat-sen UniversityOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT02180724 | An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia | active not recruiting | Phase 2 | 107 | Acerta Pharma BVINDUSTRY | 7 | Sep 14, 2026 | clinicaltrials |
| NCT03267433 | Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission | active not recruiting | Phase 3 | 689 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Sep 14, 2026 | clinicaltrials |
| NCT04075292 | Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia | active not recruiting | Phase 3 | 155 | AstraZenecaINDUSTRY | 5 | Sep 14, 2026 | clinicaltrials |
| NCT04115631 | A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma | active not recruiting | Phase 2 | 360 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04128501 | Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting | active not recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04246086 | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma | active not recruiting | Phase 1 / Phase 2 | 237 | Hoffmann-La RocheINDUSTRY | 5 | Sep 14, 2026 | clinicaltrials |
| NCT04270266 | Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma | active not recruiting | N/A | 71 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06242834 | Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma | active not recruiting | Phase 2 | 11 | Northwestern UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06765876 | CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial(UHKT-CAR123-01) | active not recruiting | Early Phase 1 | 18 | Institute of Hematology and Blood Transfusion, Czech RepublicOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01318317 | Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 8 | City of Hope Medical CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT01849263 | Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma | active not recruiting | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 3 | Sep 11, 2026 | clinicaltrials |
| NCT03517137 | Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study(COBRA) | active not recruiting | Phase 2 | 150 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 7 | Sep 11, 2026 | clinicaltrials |
| NCT03922724 | Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma | active not recruiting | Phase 2 | 91 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04571138 | A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma | active not recruiting | Phase 1 / Phase 2 | 35 | Seattle Children's HospitalOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04665765 | Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | active not recruiting | Phase 2 | 41 | City of Hope Medical CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04965155 | A Trial for Relapsed Multiple Myeloma Patients (Isatuximab-dexamethasone)(ISABEL) | active not recruiting | Phase 2 | 50 | EMN Trial Office S.r.l. Impresa SocialeOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05201248 | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 49 | GenmabINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05300282 | Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients(FIL_A-BEGEV) | active not recruiting | Phase 1 / Phase 2 | 122 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06251180 | Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 112 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06291220 | A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)(453 Ph1 CLL) | active not recruiting | Phase 1 | 4 | AbbVieINDUSTRY | 5 | Sep 11, 2026 | clinicaltrials |
| NCT06492837 | Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients(FIL_MOZART) | active not recruiting | Phase 2 | 56 | Fondazione Italiana Linfomi - ETSOTHER | 2 | Sep 11, 2026 | clinicaltrials |
| NCT07342114 | A Clinical Study to Evaluate the Effects of RO7875913 in Healthy Participants and of RO7875913 With Cevostamab in Participnats With With Relapsed/Refractory Multiple Myeloma | active not recruiting | Phase 1 | 240 | Genentech, Inc.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT02835911 | Clinical Cohort of Lymphoma Patients in Malawi | active not recruiting | — | 1,140 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT04759586 | Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma | active not recruiting | Phase 3 | 244 | National Cancer Institute (NCI)NIH | 4 | Sep 10, 2026 | clinicaltrials |
| NCT05589896 | A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies | active not recruiting | Phase 1 / Phase 2 | 12 | Ossium Health, Inc.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07814170 | A Manualised Post-Traumatic Growth Intervention For People With Hematological Cancers In Greece | active not recruiting | N/A | 80 | University of West AtticaOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT03625037 | First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma(EPCORE™ NHL-1) | active not recruiting | Phase 1 / Phase 2 | 666 | GenmabINDUSTRY | 15 | Sep 9, 2026 | clinicaltrials |
| NCT04124497 | A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients(DPd) | active not recruiting | Phase 2 | 45 | Fondazione EMN Italy OnlusOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04542824 | Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)(EPCORE™ NHL-3) | active not recruiting | Phase 1 / Phase 2 | 78 | GenmabINDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04623541 | Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome(EPCORE™ CLL-1) | active not recruiting | Phase 1 / Phase 2 | 194 | GenmabINDUSTRY | 12 | Sep 9, 2026 | clinicaltrials |
| NCT04663347 | Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)(EPCORE™ NHL-2) | active not recruiting | Phase 1 / Phase 2 | 543 | GenmabINDUSTRY | 13 | Sep 9, 2026 | clinicaltrials |
| NCT05595577 | Improving Exercise Capacity With a Tailored Physical Activity Intervention(PALS) | active not recruiting | N/A | 105 | Wake Forest University Health SciencesOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06311227 | Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia | active not recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07387471 | Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) | active not recruiting | Phase 2 | 14 | AbbVieINDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT01044069 | Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 | active not recruiting | Phase 1 | 93 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT04439136 | Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B) | active not recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT06539338 | A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment(INVISE) | active not recruiting | Phase 1 | 10 | Kite, A Gilead CompanyINDUSTRY | 2 | Sep 8, 2026 | clinicaltrials |
| NCT01695941 | Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT03964090 | Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) | active not recruiting | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04609046 | Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma | active not recruiting | Phase 1 | 47 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04680052 | A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.(InMIND) | active not recruiting | Phase 3 | 654 | Incyte CorporationINDUSTRY | 28 | Sep 4, 2026 | clinicaltrials |
Data updated 15 days agoSource updated Sep 15, 2026source: clinicaltrials